WallStreetZenWallStreetZen

NASDAQ: VYNE
Vyne Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

VYNE past revenue growth

How has VYNE's revenue growth performed historically?
Company
-11.11%
Industry
148.4%
Market
16.96%
VYNE's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
VYNE's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
VYNE's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

VYNE earnings and revenue history

Current Revenue
$424.0k
Current Earnings
-$28.5M
Current Profit Margin
-6,710.4%

VYNE Return on Equity

Current Company
-79.1%
Current Industry
-63.5%
Current Market
188%
VYNE's Return on Equity (-79.1%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when VYNE announces earnings.

VYNE Return on Assets

Current Company
-64.2%
Current Industry
2.9%
VYNE is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

VYNE Return on Capital Employed

Current Company
-31.56%
Current Industry
19.5%
VYNE has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

VYNE vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
VYNE$424.00k-$28.45M-$28.45M-34.79%N/A
UNCY$0.00-$30.18M-$31.41MN/AN/A
OKYO$0.00-$13.18M-$13.27MN/AN/A
XLO$0.00-$74.50M-$76.40MN/AN/A
CARA$20.97M-$115.58M-$118.51M+9.26%N/A
View Top Biotech Stocks

VYNE earnings dates

Next earnings date
May 9, 2024

Vyne Therapeutics Earnings & Revenue FAQ

What were VYNE's earnings last quarter?

On Invalid Date, Vyne Therapeutics (NASDAQ: VYNE) reported Q4 2023 earnings per share (EPS) of $4.04, up 230.32% year over year. Total Vyne Therapeutics earnings for the quarter were -$6.19 million. In the same quarter last year, Vyne Therapeutics's earnings per share (EPS) was -$3.10.

If you're new to stock investing, here's how to buy Vyne Therapeutics stock.

What was VYNE's earnings growth in the past year?

As of Q2 2024, Vyne Therapeutics's earnings has grown year over year. Vyne Therapeutics's earnings in the past year totalled -$28.45 million.

What is VYNE's earnings date?

Vyne Therapeutics's earnings date is Invalid Date. Add VYNE to your watchlist to be reminded of VYNE's next earnings announcement.

What was VYNE's revenue last quarter?

On Invalid Date, Vyne Therapeutics (NASDAQ: VYNE) reported Q4 2023 revenue of $76.00 thousand up 1,166.67% year over year. In the same quarter last year, Vyne Therapeutics's revenue was $6.00 thousand.

What was VYNE's revenue growth in the past year?

As of Q2 2024, Vyne Therapeutics's revenue has grown -11.11% year over year. This is 159.51 percentage points lower than the US Biotechnology industry revenue growth rate of 148.4%. Vyne Therapeutics's revenue in the past year totalled $424.00 thousand.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.